brain-derived

Brain-derived acidic fibroblast growth factor (brain-derived aFGF) (1-11) is a peptide fragment of brain-derived aFGF. Brain-derived aFGF is an angiogenic vascular endothelial cell mitogen produced in bovine brain that has sequence homology to interleukin-1. aFGF (1-11) corresponds to amino acid residues 1-11 of the full length peptide.

Brain-derived acidic fibroblast growth factor (102-111) is a peptide fragment of brain-derived acidic fibroblast growth factor (aFGF). aFGF is an angiogenic vascular endothelial cell mitogen produced in bovine brain that has sequence homology to interleukin-1. It also shares sequence homology with the known neuropeptides neuromedin C , bombesin , neuromedin K , substance K , substance P , physalaemin, and eledoisin. aFGF (102-111) corresponds to amino acid residues 102-111 of the fulllength peptide.

Brain-derived basic fibroblast growth factor (1-24) (brain-derived bFGF) is a peptide fragment of brain-derived bFGF. bFGF is a peptide produced in bovine brain that is protective in a rat model of pressure-induced retinal ischemia. bFGF (1-24) corresponds to amino acid residues 1-24 of the full length peptide.

Moclobemide (Ro111163) 是可逆的、可透过血脑屏障的单胺氧化酶 (MAO-A) 抑制剂，能够抑制 hMAO-A (IC50=6.061 μM)。它上调慢性应激小鼠海马祖细胞的增殖。

Brain Derived BasicFibroblast Growth Factor(1-24) (FGF basic 1-24) 是一种合成肽，表现出抗细菌和抗HBV 的活性。Brain Derived BasicFibroblast Growth Factor(1-24) 可用于感染性疾病和免疫性疾病的研究。

Brain Derived Acidic Fibroblast Growth Factor (1-11) 是多肽分子，其序列是 PALPEDGGSGAFPPGHFKDPKRLY。

Brain Derived Acidic Fibroblast Growth Factor (102-111) 是多肽分子，其序列是 HAEKHWFVGL。

Sonlicromanol hydrochloride (KH176 hydrochloride) 是可透过血脑屏障的 ROS-redox 调节剂，具有潜在的抗癌活性， 可改善 iPSC 衍生神经元中与 m.3243A>G 异质相关的神经元网络功能障碍和转录组变化，可用于治疗线粒体疾病。

4-Methylcatechol (3,4-Dihydroxytoluene) 是 p-toluate 的代谢物，它是 Catechol 2,3-Dioxygenase 的自杀性底物抑制剂。

Hemopressin (rat) acetate(568588-77-2 free base) 是一种衍生自血红蛋白 α1 链的九肽，起初是从大鼠脑匀浆中分离出来的。 Hemopressin 是 CB2 大麻素受体的口服活性、选择性和反向激动剂。 Hemopressin 在炎性疼痛模型中发挥镇痛作用。

Pramiracetam (CI-879) 来源于piracetam，能改善脑外伤引起的认知障碍。它是更有效的促智药物。

Tandutinib (CT53518) 是一种选择性 FLT3抑制剂，其 IC50为 0.22 μM。它还抑制c-Kit 和PDGFR，其IC50分别为 0.17 μM 和 0.20 μM。它可穿透血脑屏障，用于急性骨髓性白血病。

tau-0N4R-IN-1（Compound 6T）作为一种穿透脑屏障的抑制剂，能够抑制tau 0N4R、2N3R及2N4R的纤维化。该化合物具有显著的抗播种效应，在体外能够剂量依赖地减少α-syn的寡聚，并阻止α-syn包涵体的形成。在小鼠微粒体中表现出稳定性，并能减少AD患者脑组织中的Aβ斑块。此外，tau-0N4R-IN-1在小鼠体内展示出优良的药代动力学特性。

BNN-20 作为合成微神经营养因子，仿效脑源性神经营养因子 (BDNF) 的功能，能特定区域地提供强效的神经保护并促进神经发生。此化合物适用于关于帕金森病的研究领域。

RNA binder 1 (Compound 4b) 是一种具备穿越血脑屏障能力的 RNA 结合剂，能够选择性结合 C9orf72 基因 G4C2 重复序列 RNA 的 G-四链体结构。在肌萎缩侧索硬化症 (ALS) 患者衍生的细胞中，RNA binder 1 可显著降低由 G4C2 重复序列生成的毒性多肽 poly(GA) 和 poly(GP) 的水平，并对反义多肽 poly(PR) 没有显著影响，展现出对正义 RNA 的选择性。RNA binder 1 可用于研究 ALS 和额颞叶痴呆 (FTD)。

EGFR-IN-91 (compound 9) 是一种可口服的有效EGFR抑制剂，能够透过血脑屏障。它能够抑制EGFRL858R/C797S 和 EGFRexon 19del/C797S，并在异种移植 (PDX) 小鼠模型中引发肿瘤消退。EGFR-IN-91 有望抑制由EGFR突变体驱动的局部和转移性非小细胞肺癌 (NSCLC)。

(2R,4R)-APDC hydrate ((2R,4R)-4-Aminopyrrolidine-2,4-dicarboxylic acid hydrate) 是一种作用于群 II 型代谢型谷氨酸受体 (mGluR) 的激动剂。(2R,4R)-APDC hydrate 通过抑制谷氨酸的释放、增强由D1受体激活引起的运动反应或降低脑源性神经营养因子 (BDNF) 水平，从而影响细胞的增殖。该化合物常用于研究癫痫及其他神经系统疾病。

PX5-9 是提升脑源性神经营养因子 (BDNF) 的一种前体药物。PX5-9 可能会用于研究与 BDNF 有关的疾病 [例如，神经退行性疾病]。

MXC-017 是一种能够穿透血脑屏障的凋亡 (apoptosis) 诱导剂，直接靶向胶质瘤干细胞 (GSCs)。它阻止辐射诱导的 GSC 形成，并增加 G0/G1 细胞周期停滞和细胞凋亡 (apoptosis)。MXC-017 具极小的脱靶效应，在高达 10 µM 的浓度下无显著细胞毒性。此外，MXC-017 显著延长了患者来源的原位异种移植 (PDOX) 胶质母细胞瘤 (GBM) 小鼠模型中配合放射治疗的中位生存期。

CGP 56999A is an antagonist of GABA(B) receptor, it enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum.

α-Casozepine 是一种源自牛奶 α-S1 酪蛋白的生物活性肽，对大脑中的 γ-氨基丁酸（GABA）受体具有亲和力，并表现出抗焦虑作用。

Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)10(11)-EpDPA is a docosahexaenoic acid epoxygenase metabolite, derived via epoxidation of the 10,11-double bond of DHA. It has been detected in rat brain and spinal cord, as well as human serum, and acts as a substrate for soluble epoxide hydrolase with a Km value of 5.1 μM. (±)10(11)-EpDPA and other epoxy metabolites of DHA are reported to demonstrate antihyperalgesic activity in inflammatory and neuropathic pain models and to potently inhibit angiogenesis and tumor growth in in vitro assays.

Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)13(14)-EpDPA is a docosahexaenoic acid epoxygenase metabolite, derived via epoxidation of the 13,14-double bond of DHA. It has been detected in rat brain and spinal cord and is a preferred substrate for soluble epoxide hydrolase with a Km value of 3.2 μM. (±)13(14)-EpDPA demonstrates antihyperalgesic activity in inflammatory and neuropathic pain models. (±)13(14)-EpDPA and other epoxy metabolites of DHA are also reported to potently inhibit angiogenesis and tumor growth in in vitro assays.

Reduced haloperidol is an active metabolite of haloperidol . It is formed via reduction of haloperidol by ketone reductase. Reduced haloperidol inhibits radioligand binding to sigma-1 and dopamine D2 receptors (Kis = 1.4 and 31 nM, respectively) and stimulates brain-derived neurotrophic factor (BDNF) secretion from CCF-SSTG1 and U87MG astrocytic glial cells. It also inhibits norepinephrine, dopamine, and serotonin (5-HT) reuptake (Kis = 21, 25, and 33 μM, respectively, in COS-7 cells expressing the human transporters). Reduced haloperidol (0.5 mg/kg) increases latency to paw withdrawal in mouse models of capsaicin- but not force-induced mechanical hypersensitivity.